Meeting News
-
IASLC Looks Back at 50 Years of Growth, Collaboration, and Progress in Lung Cancer
A special plenary at WCLC 2024 recognized a half-century of advances in thoracic oncology while reflecting on how far the IASLC has come since its first meeting.
-
Study Shows Patients at Lowest Risk May Benefit from Longer Intervals Between Lung Cancer Screening
Dr. Annette McWilliams says the PanCan nodule management protocol demonstrates potential to streamline lung cancer screening and management processes.
-
Analyzing the CheckMate Trials: How do Clinicians Choose the Winning Strategy for Patients With Resectable NSCLC?
During WCLC 2024, Dr. Patrick Forde presented data from the CheckMate 77T and CheckMate 816 trials that may help guide lung cancer management in the near future.
-
Phase II FLOWERS Trial Unveils Potential New First-Line Therapy Option
Results from the study, presented by Dr. Jin-Ji Yang, suggest that a combination regimen of osimertinib plus savolitinib may be superior to osimertinib alone for EGFR-mutated NSCLC.
-
Analysis of Membrane-Bound TROP2 in TROPION-Lung01 Underscores Seminal Advance in Lung Cancer Digital Pathology
A novel computational pathology approach reveals the potential of TROP2 as a predictor of response to anti-TROP2 therapy in NSCLC.
-
FURTHER Study Moves the Needle Farther on Targeted Therapy Directed at Atypical EGFR Mutations in NSCLC
Furmonertinib, an oral, brain-penetrant, mutation-selective EGFR TKI, demonstrates activity in patients with EGFR PACC mutations.
-
Aumolertinib After CRT Significantly Improves PFS in EGFR-mutated Unresectable NSCLC
The third-generation EGFR TKI joins osimertinib in demonstrating a meaningful progression-free survival benefit for consolidation following chemoradiation.
-
Closing Plenary Will Focus on the Importance of Advancing Patient Advocacy
Experts will focus on overcoming barriers in patient advocacy on a global basis and enhancing the patient-physician partnership.
-
IASLC Lectureships Focus on Contributions of Leaders in Thoracic Oncology
Tuesday morning, nine expert clinicians and researchers in the field will give award lectures in honor of their contributions to the treatment of lung cancer.
-
Session to Report Results of IASLC’s First Diversity, Equity, and Inclusion Survey
Drs. Narjust Florez and Cecilia Pompili will co-chair the session, which will also include tips for improving inclusion in clinical trials, creating a mutually respective work environment, and more.
View ILCN Archives
Provider Resources